Changes in dietary intake improve glycemic control following a structured nutrition therapy during Ramadan in individuals with type 2 diabetes

2021 ◽  
Author(s):  
Barakatun-Nisak Mohd Yusof ◽  
Farah Yasmin Hasbullah ◽  
Aainaa Syarfa Mohd Shahar ◽  
Noraida Omar ◽  
Zalina Abu Zaid ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Dietary Intake ◽  
Nutrition Therapy

scholarly journals Genistein ameliorates hyperglycemia in a mouse model of nongenetic type 2 diabetes

2012 ◽  
Vol 37 (3) ◽  
pp. 480-488 ◽  
Author(s):  
Zhuo Fu ◽  
Elizabeth R. Gilbert ◽  
Liliane Pfeiffer ◽  
Yanling Zhang ◽  
Yu Fu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Sensitivity ◽  
Glycemic Control ◽  
Mouse Model ◽  
Dietary Intake ◽  
Cell Mass ◽  
Diabetic Mice ◽  
Β Cell ◽  
And Function

While peripheral insulin resistance is common during obesity and aging in mice and people, the progression to type 2 diabetes (T2D) is largely due to loss of β-cell mass and function through apoptosis. We recently reported that genistein, a soy derived isoflavone, can improve glycemic control and β-cell function in insulin-deficient diabetic mice. However, whether it can prevent β-cell loss and diabetes in T2D mice is unknown. Our current study aimed to investigate the effect of dietary supplemented genistein in a nongenetic T2D mouse model. Nongenetic, middle-aged obese diabetic mice were generated by high fat diet and a low dose of streptozotocin injection. The effect of dietary supplementation of genistein on glycemic control and β-cell mass and function was determined. Dietary intake of genistein (250 mg·kg–1 diet) improved hyperglycemia, glucose tolerance, and blood insulin level in obese diabetic mice, whereas it did not affect body weight gain, food intake, fat deposit, plasma lipid profile, and peripheral insulin sensitivity. Genistein increased the number of insulin-positive β-cell in islets, promoted islet β-cell survival, and preserved islet mass. In conclusion, dietary intake of genistein could prevent T2D via a direct protective action on β-cells without alteration of periphery insulin sensitivity.

scholarly journals Cardiovascular Adverse Outcomes as Challenges on Glycemic Variability Among Patients with Type 2 Diabetes on Intensive Insulin Therapy: The Role of Medical Nutrition Therapy with Automatic Snacking

2021 ◽  
Vol 3 (2) ◽  
pp. 59-68
Author(s):  
Leilani B Mercado-Asis ◽  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Therapy ◽  
Intensive Insulin Therapy ◽  
Glycemic Variability ◽  
Nutrition Therapy ◽  
Medical Nutrition Therapy ◽  
Type 2 Dm ◽  
Medical Nutrition

The glycemic variability (GV) is the fluctuation of the blood glucose (BG) in relation to the daily mean BG or mean glycosylated hemoglobin (HbA1c). BG oscillations can be influenced by the type of food and timing of intake, activity, psychological condition (fear of hypoglycemia), and systemic hormonal cross-talking between insulin and glucagon. Pharmacologically, these BG oscillations can be affected by the regulators of insulin secretion like sulfonylurea and insulin. The increase in GV with very high and very low BG excursions has been associated with the development of macrovascular and microvascular complications among type 2 diabetes mellitus (DM) patients. Increased mortality has been demonstrated in the past among elderly patients on intensive insulin therapy due to severe hypoglycemia. Prompt intake of glucose has obviously compromised glycemic control and worsens the GV. Automatic snacking (AS) as a part of medical nutrition therapy (MNT) is the provision of snacks 2 h after meals which are taken even in the absence of hunger. This review will showcase our published papers among patients with type 2 DM where AS was instituted to obtain long-term glycemic control and prevent the occurrence of fatal postprandial hypoglycemia. Although, further research is needed, AS is a promising dietary management to address GV in type 2 DM patients on intensive insulin therapy.

Abstract #281 Depression in type 2 Diabetes: Relationship with Duration of Diabetes, Glycemic Control, Medications and Complications

2019 ◽  
Vol 25 ◽  
pp. 112-113
Author(s):  
Sandeep Tak ◽  
Ravi Mangalia ◽  
Rajkumar Rathore ◽  
Banshi Saboo
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Duration Of Diabetes

Abstract #298: Maintaining Glycemic Control on GLA-300 While Decreasing Hypoglycemia in an Aging Type 2 Diabetes (T2D) Population: 12-Month Results (Edition 2, Edition 3)

2016 ◽  
Vol 22 ◽  
pp. 84
Author(s):  
Medha Munshi ◽  
Jasvinder Gill ◽  
Jason Chao ◽  
Elena Nikonova ◽  
Meenakshi Patel
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control
Sign in / Sign up

Export Citation Format

Share Document